TNFα Monoclonal Antibody for Acute Spinal Cord Injury

About this trial

This is a trial recruiting individuals with acute (less than two weeks) spinal cord injuries to test the effect of an anti-inflammatory treatment. While a spinal cord injury produces immediate damage, there are also delayed, secondary negative effects such as those caused by inflammation. The natural molecule TNFα triggers inflammatory responses. TNFα can be blocked, however, using a specific antibody. This study will investigate the effects of a TNFα antibody injected directly under the skin surface. If included, participants will be randomly assigned to one of three study groups: a) receiving an injection of the TNFα antibody; b) receiving an injection of a conventional anti-inflammatory drug (methylprednisolone); or c) receiving a placebo injection (no therapeutic effect). The injection will be performed after admission to the hospital and before any surgery to stabilize the spine. Final testing, including changes in sensory and motor function, will be performed after 12 months.